BioNTech Pushes 25+ Oncology Trials Forward; Validation Readiness Becomes the Commercial Test

BioNTech has appointed Guido Oelkers as its next CEO as the German biotech prepares for a decisive return to oncology. Oelkers will take office by February 1, 2027, at the latest, inheriting falling COVID-19 vaccine sales, a deep cancer pipeline